<DOC>
	<DOCNO>NCT00321256</DOCNO>
	<brief_summary>This research project support multicentric network collaborator whose goal ass efficacy transplant allogenic pancreas islet restore insulin secretion patient brittle type 1 , insulin-dependent diabetes mellitus improve metabolic control .</brief_summary>
	<brief_title>Human Islet Transplantation Brittle Type 1 Diabetes Mellitus . The GRAGIL 2 Study .</brief_title>
	<detailed_description>The general objective demonstrate beneficial effect islet allotransplantation patient brittle type 1 diabetes endogenous insulin secretion , risk spontaneous course disease judge bad transplantation-related risk . The specific objective establish reference data islet transplantation non-uremic patient brittle diabetes , multicentric network setting , use Edmonton protocol .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Inclusion criterion : Type 1 diabetes mellitus Disease duration &gt; 5 year Despite intensive insulin therapy tight endocrinologist supervision , persistence follow condition : hypoglycemia unawareness ( &lt; 54 mg/dl ) ; brittleness least two episode severe hypoglycemia ( ( define need assistance correct blood glucose level ) ketoacidosis per year , often enough diabetologist judge frequency lifethreatening , risk transplantation immunosuppression judge less risk spontaneous course uncontrolled diabetes Basal stimulate plasma Cpeptide &lt; 0.2 ng/ml Creatinine clearance ≥ 50 ml/min/1.73 m2 proteinuria &lt; 0.5 g/24h Exclusion criterion : Severe cardiovascular disease ( recent myocardial infarction , unstable coronaropathy… ) Severe systemic infection , include hepatitis C B viral infection , HIV infection tuberculosis Past present neoplasia ( exception non melanoma skin cancer ) Body weight &gt; 70 kg woman BW &gt; 75 kg men BMI &gt; 26 Stimulated Cpeptide ≥ 0.3 ng/ml upon Glucagon Arginine stimulation Age &lt; 18 year &gt; 65 year Creatinine clearance &lt; 50 ml/min/1.73 m2 Albuminuria &gt; 300 mg /24h proteinuria &gt; 0.5 g/24h Hemoglobinemia &lt; 120 g/l woman &lt; 130 g/l men Liver disease ( enzymes &gt; 1.5 N ) cirrhosis hepatitis Liver hemangioma Untreated proliferate diabetic retinopathy Pregnancy , lactation , pregnancy project absence efficient contraception Previous transplantation immunization judge antiHLA antibody ( &gt; 20 % ) Insulin need &gt; 0.7 IU/kg/d &gt; 50 IU HbA1c &gt; 12 % Any medical condition need chronic use steroid Addison disease Any hemostasis disorder need prolonged treatment anticoagulation drug . Lowdose aspirin permit . coagulation disorder contraindicate procedure , platelet count &lt; 100000/mm3 . Serious lifethreatening disease Medical surgical history potentially influencing absorption , distribution , metabolism clearance drug Uncontrolled hypercholesterolemia ( &gt; 350 mg/dl , 9.1 mmol/l ) hypertriglyceridemia ( &gt; 500 mg/dl , 5.6 mmol/l ) Leukocytes &lt; 4500/mm3 , neutrophil &lt; 2000/mm3 , platelet &lt; 100000/mm3 Any medical psychosocial condition susceptible interfere study , drug abuse recent alcohol abuse Poor therapeutic observance Failure communicate cooperate investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>islet transplantation</keyword>
	<keyword>brittle diabetes</keyword>
	<keyword>severe hypoglycemia</keyword>
	<keyword>type 1 diabetes mellitus</keyword>
</DOC>